Virax Biolabs Group Limited
VRAXHealthcare|Biotechnology|GB
$0.79
-0.39 (-32.89%)
DCF Value
$14.60
Tangible Book / Share
$18.45
Cash / Share
$16.39
Financials
Financial Snapshot
Market Cap
$1.1M
Enterprise Value
-$5.0M
Revenue (TTM)
$20.4K
Net Income (TTM)
-$13.4M
Cash & Investments
$6.5M
Net Cash
$6.1M
Free Cash Flow (TTM)
-$13.1M
Operating CF (TTM)
-$12.1M
Debt/Equity
0.05
Cash Runway & Burn Rate
Cash on Hand
$6.5M
Quarterly Burn
$3.0M
Monthly Burn
$1.0M
Est. Runway
~2.2 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $22.6K | $17.6K | $21.8K | $9.4M | $3.6M | $4.2M | $6.5M | $6.5M | |
| Operating Cash Flow | -$744.6K | -$590.2K | -$809.1K | -$4.2M | -$6.2M | -$4.6M | -$4.6M | -$12.1M | |
| Free Cash Flow | -$744.6K | -$590.2K | -$809.1K | -$4.4M | -$7.4M | -$5.2M | -$4.9M | -$13.1M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$178.4K | -$1.2M | -$603.9K | -$255.8K | -$1.0M | |
| Financing Cash Flow | $704.6K | $585.2K | $813.2K | $13.7M | $1.6M | $5.8M | $7.1M | $14.9M |
R&D Spending
R&D (TTM)
$6.9M
R&D Intensity
33876.4%
R&D Growth vs Prior
+84.5%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99.9K | $123.8K | $0.00 | $8.6K | $156.4K | $6.3K | $12.4K | $20.4K | |
| R&D Expense | $87.0K | $120.2K | $433.7K | $397.1K | $1.6M | $1.8M | $3.7M | $6.9M | |
| R&D % of Revenue | 87.1% | 97.1% | — | 4638.6% | 998.6% | 28112.5% | 30092.2% | 33876.4% | |
| SG&A | $610.0K | $514.9K | $1.3M | $5.3M | $4.6M | $4.3M | $2.7M | $8.0M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99.9K | $123.8K | $0.00 | $8.6K | $156.4K | $6.3K | $12.4K | $20.4K | |
| Cost of Revenue | $54.1K | $133.3K | $0.00 | $9.9K | $105.8K | $59.4K | $4.7K | $281.2K | |
| Gross Profit | $45.7K | -$9.4K | $0.00 | -$1.4K | $50.6K | -$53.1K | $7.7K | -$260.8K | |
| R&D | $87.0K | $120.2K | $433.7K | $397.1K | $1.6M | $1.8M | $3.7M | $6.9M | |
| SG&A | $610.0K | $514.9K | $1.3M | $5.3M | $4.6M | $4.3M | $2.7M | $8.0M | |
| Operating Income | -$651.2K | -$644.5K | -$1.7M | -$5.7M | -$6.5M | -$6.2M | -$6.4M | -$15.1M | |
| Interest Expense | $90.7K | $28.6K | $15.4K | $15.5K | $26.9K | $58.2K | $61.8K | $150.9K | |
| Pretax Income | -$739.5K | -$672.9K | -$1.7M | -$5.5M | -$6.7M | -$6.2M | -$5.9M | -$14.8M | |
| Net Income | -$801.1K | -$651.0K | -$1.7M | -$5.5M | -$6.7M | -$6.1M | -$5.0M | -$13.4M | |
| EPS (Diluted) | -17.50 | -14.25 | -37.50 | -128.25 | -84.00 | -48.75 | -12.64 | -66.14 | |
| EBITDA | $2.5K | $266.00 | -$750.00 | -$5.4M | -$6.6M | -$5.8M | -$5.4M | -$13.8M | |
| Shares Out. (M) | 0.05 | 0.05 | 0.05 | 0.04 | 0.08 | 0.12 | 0.40 | 0.40 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.6K | $17.6K | $21.8K | $9.4M | $3.6M | $4.2M | $6.4M | $6.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $79.3K | $79.3K | |
| Total Current Assets | $22.6K | $39.6K | $48.7K | $9.6M | $4.4M | $4.9M | $6.8M | $6.8M | |
| Total Assets | $22.6K | $94.1K | $48.7K | $9.8M | $5.5M | $6.4M | $8.3M | $8.3M | |
| Total Current Liabilities | $1.2M | $871.4K | $1.2M | $908.4K | $168.8K | $673.2K | $685.0K | $685.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.2M | $871.4K | $1.2M | $908.4K | $345.2K | $964.8K | $989.8K | $989.8K | |
| Stockholders' Equity | -$1.1M | -$596.2K | -$974.6K | $9.1M | $5.4M | $5.7M | $7.6M | $7.6M | |
| Retained Earnings | -$4.0M | -$4.6M | -$6.3M | -$11.8M | -$18.5M | -$24.6M | -$29.6M | -$29.6M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$744.6K | -$590.2K | -$809.1K | -$4.2M | -$6.2M | -$4.6M | -$4.6M | -$12.1M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$178.4K | -$1.2M | -$603.9K | -$255.8K | -$1.0M | |
| Free Cash Flow | -$744.6K | -$590.2K | -$809.1K | -$4.4M | -$7.4M | -$5.2M | -$4.9M | -$13.1M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | -$178.4K | -$1.2M | -$603.9K | -$255.8K | -$1.0M | |
| Financing Cash Flow | $704.6K | $585.2K | $813.2K | $13.7M | $1.6M | $5.8M | $7.1M | $14.9M | |
| Issuance of Stock | $0.00 | $403.2K | $519.6K | $13.7M | $234.00 | $5.1M | $2.8M | $15.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $100.0K | $146.3K | -$206.3K | -$107.8K | -$109.5K | -$188.2K | |
| Stock Based Comp. | $0.00 | $0.00 | $290.4K | $1.7M | $1.0M | $365.3K | $130.4K | $760.7K | |
| Net Change in Cash | -$40.0K | -$5.0K | $4.1K | $9.3M | -$5.8M | $639.7K | $2.2M | $2.0M |
Dilution Tracker
Shares outstanding grew 773.9% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+773.9%
Stock Issuance (TTM)
$15.2M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.05 | 0.05 | 0.05 | 0.04 | 0.08 | 0.12 | 0.40 | 0.40 | |
| Change vs Prior % | — | 0.0% | 0.0% | -6.5% | 88.8% | 54.7% | 220.3% | 0.0% | |
| Stock Issuance | $0.00 | $403.2K | $519.6K | $13.7M | $234.00 | $5.1M | $2.8M | $15.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $290.4K | $1.7M | $1.0M | $365.3K | $130.4K | $760.7K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 45.8% | -7.6% | — | -15.9% | 32.3% | -838.2% | 61.9% | -1280.8% | |
| Operating Margin % | -652.1% | -520.5% | — | -66963.7% | -4153.3% | -97344.8% | -51515.2% | -74394.0% | |
| Net Margin % | -802.1% | -525.8% | — | -63748.3% | -4304.8% | -95739.2% | -40439.1% | -65925.6% | |
| EBITDA Margin % | 2.5% | 0.2% | — | -63570.7% | -4225.3% | -91649.5% | -43722.4% | -67955.1% | |
| FCF Margin % | -745.5% | -476.6% | — | -50907.3% | -4738.2% | -81621.6% | -39263.6% | -64385.1% | |
| ROE % | 75.9% | 109.2% | 175.3% | -59.8% | -125.5% | -106.4% | -66.3% | -114.2% | |
| ROA % | -3543.4% | -691.7% | -3508.5% | -55.6% | -122.8% | -94.3% | -60.3% | -88.4% | |
| ROIC % | 142.9% | 82.9% | 144.9% | -63.3% | -121.1% | -103.2% | -70.1% | -100.0% | |
| R&D / Revenue % | 87.1% | 97.1% | — | 4638.6% | 998.6% | 28112.5% | 30092.2% | 33876.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 24.0% | -100.0% | 0.0% | 1727.1% | -96.0% | 96.2% | |
| Gross Profit | 0.0% | -120.6% | 100.0% | 0.0% | 3806.2% | -204.9% | 114.5% | |
| Operating Income | 0.0% | 1.0% | -169.0% | -230.7% | -13.3% | 5.1% | -3.8% | |
| Net Income | 0.0% | 18.7% | -162.5% | -219.4% | -23.4% | 10.0% | 17.1% | |
| EPS (Diluted) | 0.0% | 18.6% | -163.2% | -242.0% | 34.5% | 42.0% | 74.1% | |
| Operating Cash Flow | 0.0% | 20.7% | -37.1% | -416.6% | -49.5% | 26.9% | -1.3% | |
| Free Cash Flow | 0.0% | 20.7% | -37.1% | -438.7% | -70.1% | 30.3% | 5.6% | |
| R&D Expense | 0.0% | 38.2% | 260.8% | -8.4% | 293.3% | 13.9% | 110.0% | |
| SG&A Expense | 0.0% | -15.6% | 152.5% | 310.3% | -13.9% | -5.8% | -38.4% | |
| Total Assets | 0.0% | 316.3% | -48.3% | 20046.2% | -44.1% | 17.2% | 29.5% | |
| Book Value / Share | 0.0% | 36.0% | -54.0% | 896.1% | -69.4% | -31.1% | -58.2% | |
| Debt | 0.0% | -76.4% | -97.9% | 3791.7% | 53.4% | 68.1% | 9.9% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -6.5% | 88.8% | 54.7% | 220.3% |
Valuation
P/E (TTM)At Loss
P/S75.91
10Y Low / Med / High9.43 / 863.44 / 2072.64
P/B0.04
10Y Low / Med / High0.27 / 0.62 / 0.81
EV/EBITDA0.62
10Y Low / Med / High0.06 / 0.71 / 778829.55
EV/Revenue-353.46
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$14.60
Tangible Book / Share
$18.45
Net Current Assets / Share
$4.34
Graham Net-Net
$13.97
Cash / Share
$16.39
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -260.00 | -319.30 | -121.33 | -1.36 | -0.22 | -0.58 | -0.44 | -0.03 | |
| P/S Ratio | 2072.64 | 1671.84 | 0.00 | 863.44 | 9.43 | 557.68 | 176.02 | 75.91 | |
| P/B Ratio | -196.01 | -347.22 | -212.41 | 0.81 | 0.27 | 0.62 | 0.29 | 0.04 | |
| EV/EBITDA | 84106.70 | 778829.55 | -275985.07 | 0.33 | 0.29 | 0.06 | 0.71 | 0.62 | |
| EV/Revenue | 2080.01 | 1673.14 | 0.00 | -211.93 | -12.08 | -50.74 | -308.93 | -353.46 |
Analyst Estimates & Quality
Altman Z-Score
-6.55
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 |
|---|---|
| Revenue | $4.0K |
| Net Income | -$2.4M |
| EPS | $-6.00 |
| # Analysts (EPS) | 1 |